ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket20073239-45ketendo-4393Research ArticleСтатьиArticlesДИНАМИКА УРОВНЯ ТТГ НА ФОНЕ ПРИЕМА НОВОЙ ЛЕКАРСТВЕННОЙ ФОРМЫ “L-ТИРОКСИНА-БЕРЛИН-ХЕМИ” ПРИ ЗАМЕСТИТЕЛЬНОЙ ТЕРАПИИ ГИПОТИРЕОЗАDynamic of TSH Level Daring Replacement of Hypothyroidism with the new Form of L-thyroxine Berlin-ChemieFadeevV
Кафедра эндокринологии
-ManuilovaYu
Кафедра эндокринологии
-MorgunovaT
Кафедра эндокринологии
-20071506200732ТОМ 3, №2 (2007)3945Copyright © Fadeev V., Manuilova Y., Morgunova T., 20072007Fadeev V., Manuilova Y., Morgunova T.Fadeev V., Manuilova Y., Morgunova T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/4393ReferencesФадеев В.В., Мельниченко Г.А. Гипотиреоз: Руководство для врачей. М.: РКИ Северо-пресс, 2002. (2-е изд., 2004).Фадеев В.В., Мельниченко Г.А. Гипотиреоз: Руководство для врачей. М.: РКИ Северо-пресс, 2002. (2-е изд., 2004).American Association of Clinical Endocrinologists, the Endocrine Society and the American Thyroid Association (2005) Joint position statement on the use and interchangeability of thyroxine products (http://www.thyroid.org/professionais/advoca cy/04_12_08_thyroxine.html и http://www.thyroid.org/professionals/education/bioequivalence.html).American Association of Clinical Endocrinologists, the Endocrine Society and the American Thyroid Association (2005) Joint position statement on the use and interchangeability of thyroxine products (http://www.thyroid.org/professionais/advoca cy/04_12_08_thyroxine.html и http://www.thyroid.org/professionals/education/bioequivalence.html).Approved Drug Products With Therapeutic Equivalence Evaluations. 23rd ed. 2003. FDA/CDER (http://www.fda.gov/cder/ob/docs/preface/ecpreface.htm)Approved Drug Products With Therapeutic Equivalence Evaluations. 23rd ed. 2003. FDA/CDER (http://www.fda.gov/cder/ob/docs/preface/ecpreface.htm)Biondi B., Palmieri E.A., Lombardi G., Fazio S. Effects of subclinical thyroid dysfunction on the heart // Ann. Intern. Med. 2002. V. 137 P. 904-914.Biondi B., Palmieri E.A., Lombardi G., Fazio S. Effects of subclinical thyroid dysfunction on the heart // Ann. Intern. Med. 2002. V. 137 P. 904-914.Blakesley V.A. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate // AAPS J. 2005. V. 30. P. 42-46.Blakesley V.A. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate // AAPS J. 2005. V. 30. P. 42-46.Braverman L.E., Utiger R.D. / Eds. Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins: 2000.Braverman L.E., Utiger R.D. / Eds. Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins: 2000.Carr D., McLeod D.T., Parry G., Thornes H.M. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotropin releasing hormone test using a sensitive thyrotropin assay with measurement of free thyroid hormones and clinical assessment // Clin. Endocrinol. 1988. V. 28. P. 325-333.Carr D., McLeod D.T., Parry G., Thornes H.M. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotropin releasing hormone test using a sensitive thyrotropin assay with measurement of free thyroid hormones and clinical assessment // Clin. Endocrinol. 1988. V. 28. P. 325-333.Data on file. Abbott Laboratories, 2003.Data on file. Abbott Laboratories, 2003.Demers L.M., Spencer C.A. NACB Laboratory Medicine Practice Guidelines - Laboratory support for the diagnosis and monitoring of thyroid disease // Thyroid. 2003. V. 13. P. 1-126.Demers L.M., Spencer C.A. NACB Laboratory Medicine Practice Guidelines - Laboratory support for the diagnosis and monitoring of thyroid disease // Thyroid. 2003. V. 13. P. 1-126.FDA (2006). DrugsFDA (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm).FDA (2006). DrugsFDA (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm).FDA Advisory Committee for Pharmaceutical Science. Briefing Document-Levothyroxine Bioequivalence. Advisory Committee Meeting. March 12-13, 2003 http://www.fda.gov/ohrms/dockets/ac/03/briefing/3926B1_02_AAbbott%20.docFDA Advisory Committee for Pharmaceutical Science. Briefing Document-Levothyroxine Bioequivalence. Advisory Committee Meeting. March 12-13, 2003 http://www.fda.gov/ohrms/dockets/ac/03/briefing/3926B1_02_AAbbott%20.docHelfand M., Redfern C.C. Screening for thyroid disease: an update // Ann. Intern. Med. 1998. V. 129. P. 144-158.Helfand M., Redfern C.C. Screening for thyroid disease: an update // Ann. Intern. Med. 1998. V. 129. P. 144-158.Hennessey J.V. Levothyroxine dosage and the limitations of current bioequivalence standards // Nature Clinical Practice Endocrinol. Metab. 2006. V. 2. P. 474-475.Hennessey J.V. Levothyroxine dosage and the limitations of current bioequivalence standards // Nature Clinical Practice Endocrinol. Metab. 2006. V. 2. P. 474-475.Paul T.L., Kerrigan J., Kelly A.M. et al. Long-term thyroxine therapy is associated with decreased hip bone density in premenopausal women // JAMA. 1988. V. 259. P. 3137-3141.Paul T.L., Kerrigan J., Kelly A.M. et al. Long-term thyroxine therapy is associated with decreased hip bone density in premenopausal women // JAMA. 1988. V. 259. P. 3137-3141.U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Levothyroxine sodium tablets-in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. Dec. 2000 (http://www.fda.gov/cder/guidance/3645fnl.pdf).U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Levothyroxine sodium tablets-in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. Dec. 2000 (http://www.fda.gov/cder/guidance/3645fnl.pdf).U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Science, Office of Generic Drugs. Electronic Orange Book. (http://www/fda.gov/cder/ob), 2003.U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Science, Office of Generic Drugs. Electronic Orange Book. (http://www/fda.gov/cder/ob), 2003.
The authors declare that there are no conflicts of interest present.